News

US to fast-track approval of certain generic biologic drugs in key policy shift

Under the new guidance, generic manufacturers would no longer be required to replicate extensive human clinical trials in order to demonstrate equivalence with an original biologic product. The FDA said companies may rely instead primarily on sophisticated analytical comparability data to prove similarity in safety, purity and effectiveness.

• By Newsdesk
• Washington
• Oct 30, 2025

News

The Food and Drug Administration (FDA) yesterday announced a major change that will relax requirements for generic biologic medicines, signalling a sharp turnaround for the biosimilar market. According to the agency, certain complex biologics engineered from living cells will now be eligible for approval under an accelerated pathway, a development that could shave years off development timelines and raise competitive pressures on innovative drug makers.

Under the new guidance, generic manufacturers would no longer be required to replicate extensive human clinical trials in order to demonstrate equivalence with an original biologic product. The FDA said companies may rely instead primarily on sophisticated analytical comparability data to prove similarity in safety, purity and effectiveness. The move could “halve the development time” and significantly reduce cost burdens for biosimilars, according to agency estimations.

“For biosimilars, clinical efficacy studies have low sensitivity compared with comparative analytical assessments,” said the FDA, noting that eliminating bulky trials and interchangeability studies would expedite access while maintaining rigorous standards.

The policy shift is also expected to loosen the “interchangeability” designation process, a regulatory status that allows pharmacists to substitute a biosimilar without physician oversight. The FDA indicated that “bureaucratic switching studies” have slowed uptake of biosimilars and that streamlined rules will encourage greater confidence in and accessibility of these drugs.

Industry watchers say the change is a blow to big-pharma firms that have long relied on biologic franchising to protect revenues. With development costs for biosimilars now potentially reduced, more entrants may flood the market, pushing down prices and forcing reference biologic manufacturers to defend their position.

The FDA’s announcement builds on earlier actions by the Department of Health and Human Services (HHS) and other regulators aimed at lowering drug costs and increasing competition in the US healthcare system. By easing barriers for biosimilar approval, regulators aim to accelerate patient access to advanced treatments for cancer, autoimmune diseases and rare disorders while redirecting innovation focus towards next-generation therapeutics.

In conjunction with the announcement, the FDA released draft guidance setting out streamlined criteria for biosimilar development. The new framework intends to shift the emphasis from large-scale human trials to a more nuanced assessment of structural and functional bio comparability reducing reliance on costly and time-consuming clinical studies.

The industry response was varied: Biosimilar developers welcomed the move as a long-awaited boost, while investor and brand-product stakeholders warned that rapid commoditisation might erode margins and discourage costly innovation. The change marks a potentially historic pivot in biologic drug policy, one that may redefine the landscape of competition and access for complex medicines in the US.

(Source: Financial Times)